In the biotech sector, daily stories (news) are not just announced, but mostly edited in ways that project the narrators’ tendencies and wishes rather than the original news. Last week’s headlines comprised positive news from a firm’s drug aimed at treating a chronic progressive disease, muscular dystrophy, which disables children’s by weakening their voluntary and involuntary muscles, while threatening their hearts and lungs and lives. Other headlines included initial attempts to defeat a detrimental virus, Zika, which threatens embryos in their mothers’ wombs, turning pregnancies, which are at the origin of humans’ existence . . .